COMMUNIQUÉS West-GlobeNewswire

Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
04/11/2026
DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
05/11/2026
ROCKVILLE, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, [...]
Neion Bio Taps John Maga as Head of Biologics and CMC to Expand Capabilities In Innovative Development
04/11/2026
Veteran biopharmaceutical executive brings deep experience across complex therapeutic modalities as Neion expands the Raptor platform for innovative and difficult-to-express proteins NEW YORK, Nov. 04, 2026 (GLOBE [...]
Pacific Health Care Organization, Inc. Reports its Third Quarter 2026 Financial Results
04/11/2026
Irvine, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed yesterday with the Securities and Exchange Commission (the “SEC”) its quarterly report on Form 10-Q [...]
Hennick Humber Hospital Opened Its Doors to 150 Students to Explore the Future of Healthcare
04/11/2026
Annual Take Our Kids to Work Day experience gave young people a firsthand look at the people, technology and career possibilities shaping modern healthcare TORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- What did the future [...]
Guidepoint Qsight Launches Consumer Sentiment Tool to Understand Motivations, Behavior & Trends in Aesthetics
04/11/2026
New York, NY, Nov. 04, 2026 (GLOBE NEWSWIRE) -- New Qsight Platform Provides Powerful Insights into Both Current and Prospective Patients in the Medical Aesthetics Market Captures the total addressable market, both [...]
New Research Suggests hERG IC₁₀ May Improve Prediction of Drug-Induced QT Prolongation
04/11/2026
NEW ORLEANS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Dr. William J. Crumb Jr., Ph.D., President and CEO of Nova Research Laboratories, LLC, has collaborated with Dr. Andrew G. Edwards, Ph.D., Chief Research Scientist of [...]
NMDP and CIBMTR to Present Innovative New Transplantation Research at ASH 2026
04/11/2026
MINNEAPOLIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- NMDP SM , a global nonprofit leader in cell therapy, and CIBMTR ® (Center for International Blood and Marrow Transplant Research ® ) its collaborative research program with [...]
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
04/11/2026
New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment Updated data to be presented from first-in-human trial of LB2501, an investigational, off [...]
Kamau Therapeutics Announces First Multi-Patient Clinical Data Showing Precise Correction of the Sickle Cell Mutation and Restoration of Adult Hemoglobin
04/11/2026
All three patients are transfusion-independent with no vaso-occlusive events; predominant adult hemoglobin profile restored, with sickle hemoglobin below 20% beyond six months Data to be featured in an oral presentation [...]
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
04/11/2026
WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that [...]
Atavistik Bio to Highlight Momentum Across Hematology Pipeline with Harmony-HHT Clinical Trial Update and New Preclinical Data from HHT and JAK2 V617F Programs at ASH 2026
04/11/2026
Harmony-HHT trial-in-progress poster to showcase the ongoing Phase 1/2 clinical study of ATV-1601, an investigational oral, AKT1-selective allosteric inhibitor targeting the underlying disease biology of hereditary [...]
Umoja Biopharma Announces Oral Presentation of First UB-VV400 In Vivo CAR T Cell Therapy Clinical Data and Four Total Presentations at the 68th ASH Annual Meeting
04/11/2026
Presentations span UB-VV400 and UB-VV410 clinical data from investigator-initiated trials and trial-in-progress posters for UB-VV400 and UB-VV500 SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja [...]
Secura Bio Announces Two Duvelisib Presentations on Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma at the 2026 American Society of Hematology Annual Meeting
04/11/2026
Phase 2 PRIMO sub-analysis highlights outcomes with duvelisib in patients with peripheral T-cell lymphoma who proceeded to stem cell transplant Novel topical formulation of duvelisib in cutaneous T-cell lymphoma [...]
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
04/11/2026
Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Safety [...]
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in- [...]
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
04/11/2026
Preclinical data supporting CITY-TFR2 for anemia of chronic disease to be presented in a poster session CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage [...]
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
04/11/2026
Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in [...]
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
04/11/2026
14 abstracts accepted at ASH 2026, including three oral presentations featuring new data across mitapivat clinical programs New analyses from RISE UP Phase 3 trial of mitapivat in sickle cell disease show durable [...]

Pages